The chemotherapeutic,
doxorubicin, is currently used empirically in the treatment of
AIDS- related
Kaposi's sarcoma (
AIDS-KS). Although often employed in a chemotherapeutic cocktail (
doxorubicin,
bleomycin,
vincristine) single-agent
therapy has recently been attempted with
liposome encapsulated
doxorubicin. Although
doxorubicin's mechanism of action against
AIDS-KS is unknown, we hypothesized that
doxorubicin's ability to undergo redox cycling is associated with its clinical efficacy. The current study was conducted to investigate the effects of
doxorubicin on selected
xenobiotic-associated biochemical responses of three cellular populations: KS lesional cells, nonlesional cells from the KS donors, and fibroblasts obtained from HIV- aged matched men. Our results show that during
doxorubicin challenge, there are strong positive correlations between cellular
glutathione (GSH) levels and viability (r = 0.94),
NADPH levels and viability (r = 0.93), and GSH and
NADPH levels (r = 0.93), and demonstrate that as a consequence of their abilities to maintain cellular
thiol redox pools HIV- donor cells are significantly less susceptible to
doxorubicin's cytotoxic effects relative to
AIDS-KS cells. Additional studies further supported the contribution of reduced
thiols in mediating
doxorubicin tolerance. While pretreatment with the GSH precursor,
N-acetylcysteine was cytoprotective for all cell groups during
doxorubicin challenge, GSH depletion markedly enhanced
doxorubicin's cytotoxic effects. Studies to investigate the effects of a
hydroxyl scavenger and
iron chelator during
doxorubicin challenge showed moderate cytoprotection in the
AIDS-KS cells but deleterious effects in the HIV control cells. Inactivation of the longer lived membrane generated ROI in the cytoprotective deficient
AIDS-KS cells, as well as an impairment of endogenous defenses in the HIV- donor control cells, may account for these scavenger and
chelator associated findings. In summary, our findings show that
doxorubicin mediates, at least in part, its
AIDS-KS cellular cytotoxic effects by a redox related mechanism, and provides a biochemical rationale for
doxorubicin's clinical efficacy in
AIDS-KS treatment.